Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENZAMET: Enzalutamide with first-line androgen deprivation therapy for metastatic prostate cancer
2014-003190-42Phase 3Active
- Sponsor
- Cancer Trials Ireland
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Cancer Trials Ireland. Started Aug 2014; status: active.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2014-003190-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003190-42.